Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants.
The cyclical exacerbations of epilepsy (catamenial epilepsy) were used to assess the antiepileptic effect of a benzodiazepine, clobazam. Doses of 20 mg, and in some cases 30 mg, per day were compared with placebo over predetermined ten-day periods in a double-blind cross-over study. The results were evaluated by preference in a sequential procedure. In 14 of 18 patients who received both treatments clobazam was superior to placebo, and in 4 patients no preference was established. Clobazam completely prevented seizures in most of the patients, and toxic effects were of low frequency and severity.
D000208:Acute Disease; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants / Q000627:therapeutic use*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000078306:Clobazam; D004311:Double-Blind Method; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008598:Menstruation
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D001570:Benzodiazepinones; D001569:Benzodiazepines; D000078306:Clobazam